News

CEO Sofia Heigis presented at Redeye event Commercialization in Life Science

Sofia Heigis presented and interviewed at Stockholm Corporate Finance Life Science Days

Oncopeptides initiates MARINA study to strengthen real-world evidence for Pepaxti in Germany

European Journal of Haematology: Real-World Data reinforces Pepaxti’s role in treatment sequencing for multiple myeloma

CEO Sofia Heigis presents Oncopeptides at Aktiespararna

Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma

Biostock: presentation and interview with Sofia Heigis

Oncopeptides CEO Sofia Heigis interviewed by Redeye about Q4 and the new share issue

CEO Sofia Heigis interviewed by Redeye

Research shows that Pepaxti is effective in high-risk myeloma

Oncopeptides presented at Stora Aktiedagarna – an Aktiespararna event in Stockholm

VIDEO NOW AVAILABLE: Oncopeptides hosted Capital Markets Update November 13